Market Mover: INmune Bio (INMB) Climbs at Midday June 23

Equities Staff  |

Shares of INmune Bio Inc (NASDAQ: INMB) are up 11.04% Thursday.

As of 11:56:16 est, INmune Bio sits at $8.25 and has climbed $0.82 per share in trading so far.

INmune Bio has moved 2.20% over the last 30 days and has moved YTD 27.16% based on the previous close.

The company is set to release earnings on 2022-08-03.

For technical charts, analysis, and more on INmune Bio visit the company profile.

About INmune Bio Inc

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

To get more information on INmune Bio Inc and to follow the company's latest updates, you can visit the company's profile page here: INmune Bio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content